Opus Genetics (NASDAQ:IRD) Upgraded at Brookline Capital Management

Brookline Capital Management upgraded shares of Opus Genetics (NASDAQ:IRD) to a strong-buy rating in a research report report published on Monday,Zacks.com reports. Brookline Capital Management also issued estimates for Opus Genetics’ Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.63) EPS, FY2026 earnings at ($0.57) EPS, FY2027 earnings at ($0.64) EPS, FY2028 earnings at ($0.68) EPS and FY2029 earnings at ($0.80) EPS.

Several other research firms have also issued reports on IRD. Weiss Ratings restated a “sell (d-)” rating on shares of Opus Genetics in a research report on Wednesday, October 8th. Wall Street Zen cut shares of Opus Genetics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Wedbush initiated coverage on Opus Genetics in a research report on Wednesday, October 29th. They set an “outperform” rating and a $8.00 target price on the stock. Piper Sandler initiated coverage on Opus Genetics in a research note on Tuesday, November 25th. They set an “overweight” rating and a $7.00 price target on the stock. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $9.00 price target on shares of Opus Genetics in a report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $7.67.

Opus Genetics Stock Performance

Shares of NASDAQ IRD opened at $2.09 on Monday. Opus Genetics has a 12 month low of $0.65 and a 12 month high of $2.37. The company has a market cap of $144.13 million, a P/E ratio of -1.11 and a beta of 0.42. The business’s 50 day moving average is $1.96 and its two-hundred day moving average is $1.42. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.18.

Opus Genetics (NASDAQ:IRD) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02. Opus Genetics had a negative return on equity of 697.94% and a negative net margin of 466.09%.The company had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $3.07 million. On average, equities analysts expect that Opus Genetics will post -1.22 EPS for the current year.

Institutional Investors Weigh In On Opus Genetics

A number of institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in shares of Opus Genetics in the 1st quarter valued at approximately $26,000. Voss Capital LP acquired a new stake in Opus Genetics in the 1st quarter valued at $147,000. Mink Brook Asset Management LLC acquired a new stake in Opus Genetics in the 1st quarter valued at $795,000. Comerica Bank bought a new stake in Opus Genetics in the first quarter valued at $29,000. Finally, BIOS Capital Management LP bought a new stake in Opus Genetics in the first quarter valued at $977,000. 14.97% of the stock is owned by institutional investors and hedge funds.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.